Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.

DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.

Ivarmacitinib effectively regrows hair in severe alopecia areata.

Erlotinib can cause hair loss as a side effect.

Cemiplimab can cause alopecia areata, but it can be treated successfully.

JAK inhibitors helped treat hair loss in two people with Down syndrome.

Topical calcitriol is safe for preventing hair loss during chemotherapy.

Diphencyprone initially increases mouse hair growth, then slows it, possibly due to changes in specific protein levels.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

Curcumin, EGCG, barringtozenol, and finasteride are effective VEGFR inhibitors.

PKM2 is a promising target for heart repair and regeneration.

Y27632 increases cell growth through EGFR signaling, not ROCK1/2.

Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.

Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.

Diphencyprone (DCP) is an effective treatment for severe alopecia areata and resistant warts, with some risks.

Targeting Keratin 17 may help overcome cancer therapy resistance.

CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.

Inactivating both p53 and Rb genes in mice speeds up aggressive skin cancer development.

Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

Certain cancer drugs are strongly linked to nerve damage, requiring close monitoring and early treatment.

New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.

Further research is needed to develop effective cancer prevention strategies.

DKK proteins could help diagnose and treat various non-cancerous diseases.

Activating PKM2 and Wnt/β-catenin signaling together can potentially enhance hair growth and could be a treatment for hair loss.

Deuruxolitinib and baricitinib are effective for treating severe alopecia areata.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.